(Q39810667)

14 September 2017

title

Pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in renal and hepatic impairment patients (English)

1 reference

14 September 2017

1 reference

1 reference

1 reference

Xuejun Chen

1

1 reference

14 September 2017

Jack G Shi

2

1 reference

14 September 2017

Thomas Emm

3

1 reference

14 September 2017

Peggy A Scherle

4

1 reference

14 September 2017

Ryan F McGee

5

1 reference

14 September 2017

Yvonne Lo

6

1 reference

14 September 2017

Robert R Landman

7

1 reference

14 September 2017

Naresh G Punwani

8

1 reference

14 September 2017

William V Williams

9

1 reference

14 September 2017

Swamy Yeleswaram

10

1 reference

14 September 2017

publication date

19 October 2013

1 reference

Clinical pharmacology in drug development

14 September 2017

published in

1 reference

14 September 2017

volume

3

1 reference

14 September 2017

issue

1

1 reference

14 September 2017

page(s)

34-42

1 reference

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms

14 September 2017

cites work

1 reference

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis

21 January 2018

1 reference

The pharmacokinetics, pharmacodynamics, and safety of orally dosed INCB018424 phosphate in healthy volunteers.

21 January 2018

1 reference

Metabolism, excretion, and pharmacokinetics of [14C]INCB018424, a selective Janus tyrosine kinase 1/2 inhibitor, in humans

21 January 2018

1 reference

Transection of the oesophagus for bleeding oesophageal varices

21 January 2018

1 reference

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

21 January 2018

1 reference

Effects of hepatic impairment on the pharmacokinetics of nilotinib: an open-label, single-dose, parallel-group study

21 January 2018

1 reference

Pharmacokinetics of a single dose of the antifungal posaconazole as oral suspension in subjects with hepatic impairment

21 January 2018

1 reference

The pharmacokinetics of escitalopram in patients with hepatic impairment

21 January 2018

1 reference

The effect of chronic renal failure on hepatic drug metabolism and drug disposition

21 January 2018

1 reference

Drug metabolism in chronic renal failure

21 January 2018

1 reference

Effects of renal failure on drug transport and metabolism

21 January 2018

1 reference

Emerging evidence of the impact of kidney disease on drug metabolism and transport

21 January 2018

1 reference

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis

21 January 2018

1 reference

JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis

21 January 2018

1 reference

The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers

21 January 2018

1 reference

7 January 2021

Pharmacokinetics, safety, and tolerability of the oral Renin inhibitor aliskiren in patients with hepatic impairment

1 reference

7 January 2021

Assessment of the impact of renal impairment on systemic exposure of new molecular entities: evaluation of recent new drug applications

1 reference

7 January 2021

When to conduct a renal impairment study during drug development: US Food and Drug Administration perspective

1 reference

7 January 2021

The Effect of Renal Failure on Hepatic Drug Clearance

1 reference

7 January 2021

Identifiers

DOI

10.1002/CPDD.77

1 reference

14 September 2017

1 reference